Fingolimod hydrochloride

Base Information

• Chemical Name: Fingolimod hydrochloride
• CAS No.: 162359-56-0
• Molecular Formula: C19H34ClNO2
• Molecular Weight: 343.93
• Hs Code.: 29221990
• European Community (EC) Number: 680-631-1
• UNII: G926EC510T
• DSSTox Substance ID: DTXSID00167364
• Wikidata: Q27132395
• NCI Thesaurus Code: C72782
• RXCUI: 1012891
• Pharos Ligand ID: 7TJCA8256R3B
• ChEMBL ID: CHEMBL544665
• Mol file: 162359-56-0.mol

Synonyms:2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride;fingolimod;fingolimod hydrochloride;FTY 720;FTY-720;FTY720;Gilenia;gilenya

Chemical Property of Fingolimod hydrochloride

Chemical Property:

• Appearance/Colour: white solid
• Vapor Pressure: 5.28E-10mmHg at 25°C
• Melting Point: 102-107 °C
• Refractive Index: 1.531
• Boiling Point: 479.5 °C at 760 mmHg
• Flash Point: 243.8 °C
• PSA: 66.48000
• Density: 1.016g/cm3
• LogP: 4.70660
• Storage Temp.: -20°C Freezer
• Solubility.: water: soluble10mg/mL, clear
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 12
• Exact Mass: 343.2278070
• Heavy Atom Count: 23
• Complexity: 258

Purity/Quality:

99.00% ^*data from raw suppliers

Fingolimod Hydrochloride ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi
• Hazard Codes: Xi
• Statements: 36/37/38-52/53
• Safety Statements: 26-61

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl
• Recent ClinicalTrials: Fingolimod in Treating Patients With Chemotherapy-Induced Neuropathy
• Recent EU Clinical Trials: A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension. Additional PIP decision number: P/014/2021
• Description: Approved by the U.S. FDA in September 2010, fingolimod (also referred to as FTY720) is the first approved oral therapy for the relapsing-remitting form ofmultiple sclerosis (RRMS). Because of fingolimod’s structural resemblance to sphingosine, a metabolite of sphingolipids that constitutes the cell membrane of all eukaryotic cells, it was hypothesized that fingolimod may be affecting sphingolipid metabolism in cells. A series of elegant in vitro and in vivo studies confirmed that fingolimod is converted to (S)-fingolimod phosphate primarily by sphingosine kinase- 2 and that (S)-fingolimod phosphate mediates multiple biological processes by binding to novel GPCR’s referred to as sphingosine-1-phosphate (S1P) receptors. S1P receptors are divided into five subtypes, S1P1–5, which have varying tissue and cellular distribution. S1P1–3 receptors are ubiquitously expressed in the immune, cardiovascular, and central nervous systems, S1P4 is restricted to the hematopoietic system, and S1P5 is mostly localized in the white matter of CNS. S1P1–3 receptors play important roles in endothelial barrier function, maintaining vascular tone, regulating heart rate and allowing for lymphocyte egress fromsecondary lymphoid organs. The functional role of S1P4 is unknown,while the S1P5 receptor is thought to be involved in natural killer cell trafficking and oligodendrocyte function.
• Uses: A derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb Iscaria sinclarii as well as a structural analogue of Sphingosine. It is a novel immune modulator that prolongs allograft transplant survival in numberour models by inhibitin Oral medicine for the treatment of multiple sclerosis FTY720 is a derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb Iscaria sinclarii as well as a structural analogue of Sphingosine. FTY720 is a novel immune modulator that prolong s allograft transplant survival in numberour models by inhibiting lymphocyte emigration from lymphoid organs. FTY720 us reported to be phosphorylated by sphingosine kinase to FTY720-P, which has been shown to potently stimulate GTPgS binding activity in S1P-transfected CHO cells (EC50 = 210 pM, 4.9 nM, 4.3 nM, and 1 nM for S1P1, S1P3, S1P4 and S1P5, respectively). A cell-permeable aminopropanediol immunosuppressive agent that displays lymphocyte sequestration properties. Fingolimod Hydrochloride is a derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb Iscaria sinclarii as well as a structural analogue of Sphingosine. Fingolimod is a novel immune modulator that prolongs allograft transplant survival in numerous models by inhibiting lymphocyte emigration from lymphoid organs. Fingolimod is reported to be phosphorylated by sphingosine kinase to FTY720-P, which has been shown to potently stimulate GTPgS binding activity in S1P-transfected CHO cells (EC50 = 210 pM, 4.9 nM, 4.3 nM, and 1 nM for S1P1, S1P3, S1P4 and S1P5, respectively).
• Clinical Use: Fingolimod hydrochloride is an immunosuppressive drug developed by Novartis and approved in the U.S., Europe, and Australia in 2010 for the treatment of multiple sclerosis. The structure of fingolimod derives from the naturally-occurring myriocin (ISP-1) metabolite of the fungus I. sinclairii and the aminoalcohol functionality within the drug possesses structural similarity to the sphingosine family of natural products.